BackgroundCheck.run
Search For

Anita A Mathias513 Porpoise Bay Ter APT G, Sunnyvale, CA 94089

Anita Mathias Phones & Addresses

513 Porpoise Bay Ter APT G, Sunnyvale, CA 94089   

Cupertino, CA   

San Jose, CA   

1201 52Nd St, Seattle, WA 98105    206-5238697   

Foster City, CA   

1201 NE 52Nd St APT 2, Seattle, WA 98105    206-5101992   

Work

Position: Production Occupations

Education

Degree: Bachelor's degree or higher
Get Report
Control this profile

Mentions for Anita A Mathias

Anita Mathias resumes & CV records

Resumes

Anita Mathias Photo 30

Executive Director - Head Of Clinical And Quantitative Pharmacology At Gilead

Location:
199 east Blaine St, Seattle, WA 98109
Industry:
Biotechnology
Work:
Gilead Sciences Jan 2016 - Nov 2018
Senior Director - Clinical and Quantitative Pharmacology Gilead Sciences Jan 2016 - Nov 2018
Executive Director - Head of Clinical and Quantitative Pharmacology at Gilead Gilead Sciences Jan 2012 - Jan 2016
Director- Clinical Pharmacology Gilead Sciences Jun 2011 - Jan 2014
Associate Director of Clinical Pharmacology Gilead Sciences Jun 2004 - Jan 2012
Clinical Research Scientist at Gilead Sciences
Education:
University of Washington 1999 - 2004
Doctorates, Doctor of Philosophy
Skills:
Research, San, Clinical Research, Clinical Pharmacology
Anita Mathias Photo 31

Anita Mathias

Publications & IP owners

Us Patents

Therapeutic Compositions And Methods

US Patent:
2009009, Apr 9, 2009
Filed:
Jun 26, 2008
Appl. No.:
12/147220
Inventors:
Brian P. Kearney - San Francisco CA, US
Anita A. Mathias - Sunnyvale CA, US
Assignee:
Gilead Sciences, Inc. - Foster City CA
International Classification:
A61K 31/5377
A61K 31/513
US Classification:
5142368, 514274
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.

Use Of Solid Carrier Particles To Improve The Processability Of A Pharmaceutical Agent

US Patent:
2009032, Dec 31, 2009
Filed:
May 1, 2009
Appl. No.:
12/434513
Inventors:
Joanna M. Koziara - Foster City CA, US
Mark M. Menning - Foster City CA, US
Reza Oliyai - Foster City CA, US
Robert G. Strickley - Foster City CA, US
Richard Yu - Foster City CA, US
Brian P. Kearney - Foster City CA, US
Anita A. Mathias - Foster City CA, US
Assignee:
GILEAD SCIENCES, INC. - Foster City CA
International Classification:
A61K 9/30
A61K 31/5377
A61K 31/675
A61P 43/00
US Classification:
424490, 5142368, 514 81
Abstract:
The invention provides a composition comprising, a compound of formula (I):or a pharmaceutically acceptable salt thereof and a plurality of solid carrier particles, as well as methods for using the composition to inhibit the activity of cytochrome P-450.

Therapeutic Compositions And The Use Thereof

US Patent:
2010033, Dec 30, 2010
Filed:
Jun 26, 2008
Appl. No.:
12/666991
Inventors:
Brian P. Kearney - Foster City CA, US
Anita A. Mathias - Foster City CA, US
Srinivasan Ramanathan - Foster City CA, US
Assignee:
ThERAPEUTIC COMPOSITONS AND USE THEREOF - FORSTER CITY
International Classification:
A61K 31/5377
A61K 31/47
A61P 31/12
US Classification:
5142368, 514312
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.

Therapeutic Compositions And The Use Thereof

US Patent:
2011000, Jan 13, 2011
Filed:
Jun 26, 2008
Appl. No.:
12/666995
Inventors:
Brian P. Kearney - Foster City CA, US
Anita A. Mathias - Foster City CA, US
Assignee:
Gilead Sciences ,Inc. - Foster City
International Classification:
A61K 31/47
A61K 31/513
A61K 31/5377
A61P 31/12
A61P 31/18
US Classification:
5142368, 514312, 514274
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.

Therapeutic Compositions And Methods

US Patent:
2009009, Apr 9, 2009
Filed:
Jun 26, 2008
Appl. No.:
12/147041
Inventors:
Brian P. Kearney - San Francisco CA, US
Anita A. Mathias - Sunnyvale CA, US
Srinivasan Ramanathan - San Carlos CA, US
Assignee:
Gilead Sciences, Inc. - Foster City CA
International Classification:
A61K 31/5513
A61K 31/47
A61P 35/00
A61K 31/5377
US Classification:
514221, 514312, 5142368
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.

Method Of Treating A Viral Infection Using Elvitegravir Combinations

US Patent:
2017013, May 18, 2017
Filed:
Oct 19, 2016
Appl. No.:
15/298070
Inventors:
- Foster City CA, US
Anita A. MATHIAS - Sunnyvale CA, US
International Classification:
A61K 31/47
A61K 31/426
A61K 31/5377
A61K 31/513
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.

Method Of Treating A Viral Infection Using Elvitegravir Combinations

US Patent:
2017013, May 18, 2017
Filed:
Oct 19, 2016
Appl. No.:
15/298084
Inventors:
- Foster City CA, US
Anita A. MATHIAS - Sunnyvale CA, US
Srinivasan RAMANATHAN - San Carlos CA, US
International Classification:
A61K 31/47
A61K 31/5377
A61K 31/4402
A61K 31/426
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.

Method Of Treating A Viral Infection Using Elvitegravir Combinations

US Patent:
2014034, Nov 20, 2014
Filed:
May 19, 2014
Appl. No.:
14/281790
Inventors:
- Foster City CA, US
Anita A. MATHIAS - Sunnyvale CA, US
Assignee:
Gilead Sciences, Inc. - Foster City CA
International Classification:
A61K 31/5377
A61K 31/513
A61K 31/426
A61K 31/47
US Classification:
5142368, 514274
Abstract:
The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.

Possible Relatives

Cynthia K Mathias  David W Mathias  Dawn A Mathias  Dean S Mathias  Dale A Mathias  Danielle M Mathias  Diane E Mathias  Anita J Johnson  Anita A Johnston  Anita R Stanford 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.